Annual EBITDA
-$71.06 M
-$76.26 M-1468.74%
31 December 2023
Summary:
Barinthus Biotherapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$71.06 million, with the most recent change of -$76.26 million (-1468.74%) on 31 December 2023. During the last 3 years, it has fallen by -$57.03 million (-406.52%). BRNS annual EBITDA is now -1468.74% below its all-time high of $5.19 million, reached on 31 December 2022.BRNS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$6.64 M
+$8.83 M+57.08%
30 September 2024
Summary:
Barinthus Biotherapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$6.64 million, with the most recent change of +$8.83 million (+57.08%) on 30 September 2024. Over the past year, it has increased by +$6.59 million (+49.82%). BRNS quarterly EBITDA is now -142.10% below its all-time high of $15.77 million, reached on 01 June 2022.BRNS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$52.89 M
+$6.59 M+11.08%
30 September 2024
Summary:
Barinthus Biotherapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$52.89 million, with the most recent change of +$6.59 million (+11.08%) on 30 September 2024. Over the past year, it has increased by +$21.66 million (+29.05%). BRNS TTM EBITDA is now -563.01% below its all-time high of $11.42 million, reached on 01 September 2022.BRNS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BRNS EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -1468.7% | +49.8% | +29.1% |
| 3 y3 years | -406.5% | +55.1% | -10.5% |
| 5 y5 years | - | - | - |
BRNS EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -1468.7% | at low | -142.1% | +71.9% | -563.0% | +29.1% |
| 5 y | 5 years | -1468.7% | at low | -142.1% | +71.9% | -563.0% | +29.1% |
| alltime | all time | -1468.7% | at low | -142.1% | +71.9% | -563.0% | +29.1% |
Barinthus Biotherapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$6.64 M(-57.1%) | -$52.89 M(-11.1%) |
| June 2024 | - | -$15.47 M(+9.6%) | -$59.49 M(-12.1%) |
| Mar 2024 | - | -$14.12 M(-15.3%) | -$67.66 M(-4.8%) |
| Dec 2023 | -$71.06 M(-1468.7%) | -$16.67 M(+26.0%) | -$71.06 M(-4.7%) |
| Sept 2023 | - | -$13.23 M(-44.0%) | -$74.55 M(+39.0%) |
| June 2023 | - | -$23.65 M(+35.0%) | -$53.62 M(+277.6%) |
| Mar 2023 | - | -$17.52 M(-13.1%) | -$14.20 M(-334.0%) |
| Dec 2022 | $5.19 M | -$20.16 M(-361.8%) | $6.07 M(-46.9%) |
| Sept 2022 | - | $7.70 M(-51.2%) | $11.42 M(-1587.5%) |
| June 2022 | - | $15.77 M(+473.4%) | -$768.00 K(-97.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $2.75 M(-118.6%) | -$32.41 M(-32.3%) |
| Dec 2021 | -$47.87 M(+241.2%) | - | - |
| Dec 2021 | - | -$14.80 M(+229.5%) | -$47.87 M(+17.3%) |
| Sept 2021 | - | -$4.49 M(-71.7%) | -$40.81 M(+16.3%) |
| June 2021 | - | -$15.87 M(+24.9%) | -$35.10 M(+53.7%) |
| Mar 2021 | - | -$12.71 M(+64.1%) | -$22.84 M(+62.8%) |
| Dec 2020 | -$14.03 M | -$7.74 M(-732.6%) | -$14.03 M(+123.2%) |
| Sept 2020 | - | $1.22 M(-133.9%) | -$6.29 M(-16.3%) |
| June 2020 | - | -$3.61 M(-7.5%) | -$7.51 M(+92.5%) |
| Mar 2020 | - | -$3.90 M | -$3.90 M |
FAQ
- What is Barinthus Biotherapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Barinthus Biotherapeutics?
- What is Barinthus Biotherapeutics annual EBITDA year-on-year change?
- What is Barinthus Biotherapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Barinthus Biotherapeutics?
- What is Barinthus Biotherapeutics quarterly EBITDA year-on-year change?
- What is Barinthus Biotherapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Barinthus Biotherapeutics?
- What is Barinthus Biotherapeutics TTM EBITDA year-on-year change?
What is Barinthus Biotherapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of BRNS is -$71.06 M
What is the all time high annual EBITDA for Barinthus Biotherapeutics?
Barinthus Biotherapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is $5.19 M
What is Barinthus Biotherapeutics annual EBITDA year-on-year change?
Over the past year, BRNS annual earnings before interest, taxes, depreciation & amortization has changed by -$76.26 M (-1468.74%)
What is Barinthus Biotherapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of BRNS is -$6.64 M
What is the all time high quarterly EBITDA for Barinthus Biotherapeutics?
Barinthus Biotherapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $15.77 M
What is Barinthus Biotherapeutics quarterly EBITDA year-on-year change?
Over the past year, BRNS quarterly earnings before interest, taxes, depreciation & amortization has changed by +$6.59 M (+49.82%)
What is Barinthus Biotherapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of BRNS is -$52.89 M
What is the all time high TTM EBITDA for Barinthus Biotherapeutics?
Barinthus Biotherapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $11.42 M
What is Barinthus Biotherapeutics TTM EBITDA year-on-year change?
Over the past year, BRNS TTM earnings before interest, taxes, depreciation & amortization has changed by +$21.66 M (+29.05%)